Novo Nordisk stock price forecast: $47.90 resistance as NVO trades flat

Traders Union
All News
Financial News
Novo Nordisk gains 0.82% on new launches

Highlights

Novo Nordisk expands its obesity treatment portfolio with oral Wegovy, enhancing patient access and market penetration.
A new telehealth partnership with Hims & Hers enables direct distribution of Wegovy and Ozempic, boosting digital reach and removing regulatory obstacles.
NVO trades in a bullish short-term channel above key support, but overbought technical signals and a projected $45.50–$47.90 range suggest near-term consolidation or pullback.

Portfolio expansion and telehealth partnership drive revenue momentum

The recent launch of the oral version of Wegovy marks a significant expansion in Novo Nordisk's portfolio, opening new channels for patient access in the competitive obesity treatment market. Ongoing sales growth for the injectable formulation further reinforces the company’s leadership in this therapeutic area, supporting upward momentum in revenue. Initiation of the partnership with Hims & Hers Health on March 26 now enables distribution of Wegovy and Ozempic through a direct-to-consumer telehealth platform, broadening digital reach and commercial opportunity. Additionally, Novo Nordisk’s withdrawal of litigation against Hims & Hers removes regulatory uncertainty for these distribution efforts.

Upward trend pressure as momentum meets overbought signals

For NVO, technical analysis highlights specific benchmarks: the price is trading above both SMA-20 ($42.12) and SMA-50 ($39.33), but remains below SMA-200 ($49.43). The Ichimoku Kijun on the daily timeframe stands at $41.86, presenting immediate support. Intraday levels reflect a trading range of $46.27 to $47.79, with price now near the lower end. Multiple technical indicators signal a divergence: while the MACD and ADX on the daily chart point to sustained upward momentum, overbought readings on the RSI (75.27), CCI (135.93), and Stoch RSI (100) caution that the asset is stretched. Bull/Bear Power confirms buyer dominance intraday, yet price action has softened after an upward opening gap. The Awesome Oscillator supports a continuation of the uptrend, but the confluence of persistent momentum and overbought conditions suggests the trend may be losing steam.

Limited upside potential as consolidation likely amid overbought stretch

In the coming five trading days, NVO is expected to fluctuate within a narrow volatility band between $45.50 and $47.90, reflecting typical volatility relative to current levels. The probability of a price increase is low, with consolidation or a modest decline favored as overbought conditions are digested. A bullish breakout above $47.90 would require renewed buying strength and could shift the focus toward the SMA-200 region, while a fall below $45.50 may prompt deeper profit-taking toward the Ichimoku Kijun near $41.86. Medium- and long-term signals from weekly indicators continue to suggest that any upside surprises remain limited unless substantial buying pressure returns.

Viktoras Karapetjanc, expert at Traders Union, sees Novo Nordisk A/S as maintaining constructive momentum following key product expansions and strategic partnerships. He believes these confirmed events support ongoing growth and enhance long-term positioning in the obesity treatment market. However, technical signals warn that the current rally is overextended, suggesting a pause or modest pullback as traders take profits. "While the underlying fundamentals remain robust, I expect NVO to consolidate above $45.50 before any new attempt to break toward the $47.90 level," says Karapetjanc.

Earlier, analysts noted that while Novo Nordisk maintained bullish momentum, elevated overbought signals highlighted the risk of a near-term pullback. The current setup reinforces these cautionary flags as technical and fundamental momentum remain stretched, making the $45.50 support level critical for traders monitoring potential consolidation or volatility in the days ahead.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.